| __timestamp | CRISPR Therapeutics AG | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 19586000 |
| Thursday, January 1, 2015 | 12573000 | 29135000 |
| Friday, January 1, 2016 | 42238000 | 42791000 |
| Sunday, January 1, 2017 | 69800000 | 49577000 |
| Monday, January 1, 2018 | 113773000 | 89209000 |
| Tuesday, January 1, 2019 | 179362000 | 69099000 |
| Wednesday, January 1, 2020 | 266946000 | 75961000 |
| Friday, January 1, 2021 | 438633000 | 90467000 |
| Saturday, January 1, 2022 | 461645000 | 74552000 |
| Sunday, January 1, 2023 | 387332000 | 91593000 |
| Monday, January 1, 2024 | 320653000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, CRISPR Therapeutics AG and Supernus Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, CRISPR Therapeutics AG increased its R&D spending by an impressive 25,500%, peaking in 2022 with a 30% higher investment than in 2020. This surge underscores their aggressive pursuit of cutting-edge gene-editing technologies. In contrast, Supernus Pharmaceuticals, Inc. maintained a more stable R&D budget, with a modest 367% increase over the same period. Their spending peaked in 2023, reflecting a strategic focus on steady growth and sustained innovation. This divergence highlights the varied approaches companies take in navigating the dynamic biotech landscape, each aiming to secure a competitive edge through strategic R&D investments.
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Comparing Innovation Spending: GSK plc and Supernus Pharmaceuticals, Inc.
Research and Development Investment: Incyte Corporation vs CRISPR Therapeutics AG
Comparing Innovation Spending: Pharming Group N.V. and Supernus Pharmaceuticals, Inc.
R&D Insights: How Lantheus Holdings, Inc. and CRISPR Therapeutics AG Allocate Funds
Research and Development Expenses Breakdown: Axsome Therapeutics, Inc. vs CRISPR Therapeutics AG
Research and Development: Comparing Key Metrics for Amneal Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development Investment: CRISPR Therapeutics AG vs Viridian Therapeutics, Inc.
PTC Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for MorphoSys AG and Supernus Pharmaceuticals, Inc.
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Supernus Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.: Strategic Focus on R&D Spending